Fortrea to Present at Upcoming J.P. Morgan Healthcare Conference
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP Investor Relations Tracy Krumme will present at the J.P. Morgan Annual Healthcare Conference in San Francisco.
The presentation and Q&A are scheduled for Tuesday, January 13, 2025 at 5:15 pm PST. A live webcast and replay will be available in the company’s Events section on Fortrea’s Investor Relations website. Investors seeking one-on-one meetings are asked to contact their banking representatives.
Positive
- None.
Negative
- None.
News Market Reaction – FTRE
On the day this news was published, FTRE gained 5.54%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.3% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $91M to the company's valuation, bringing the market cap to $1.73B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: MRVI up 11.14%, ATAI up 1.31%, while QURE fell 2.33% and EYPT slipped 0.63%. FTRE’s -1.13% move appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Inducement equity awards | Neutral | +5.2% | RSU grants to new hires under inducement plan, modest governance update. |
| Dec 04 | Strategic collaboration | Positive | -0.7% | Cell and gene therapy collaboration aligning CDMO manufacturing and CRO services. |
| Nov 25 | Conference participation | Neutral | +7.0% | Announcement of CEO/CFO participation in Citi and Evercore healthcare conferences. |
| Nov 24 | Debt tender offer | Positive | +9.6% | Completion of <b>$75.743M</b> senior notes repurchase funded with cash on hand. |
| Nov 17 | Leadership change | Neutral | -6.0% | Appointment of new general counsel and chief compliance officer to leadership team. |
Recent news often saw positive reactions to financial and capital-structure actions, while strategic collaborations and leadership changes produced more mixed responses.
Over the last few months, Fortrea reported several corporate updates. A $75.743 million senior notes tender on Nov 21, 2025 using cash on hand drew a strong positive reaction. Q3 2025 results in the 10‑Q showed revenue of $701.3 million with narrowed operating loss but significant earlier goodwill impairments. Conference participation in early December also coincided with gains, while a strategic collaboration announcement and a new general counsel appointment produced more muted or negative moves. Today’s J.P. Morgan conference appearance fits the pattern of ongoing investor outreach and conference activity.
Market Pulse Summary
The stock moved +5.5% in the session following this news. A strong positive reaction aligns with prior instances where Fortrea’s financial or capital-structure updates, such as the $75.743 million notes tender, drew upbeat responses. Conference announcements have previously coincided with gains as well. However, the stock already trades well above its 200-day MA of $8.58, and past moves have not been uniformly positive across all news types, suggesting that sharp spikes could be vulnerable if expectations from the event schedule are not met in later disclosures.
AI-generated analysis. Not financial advice.
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the following conference in January:
| J.P. Morgan Annual Healthcare Conference (San Francisco) | |
| Date: | Tuesday, January 13, 2025 |
| Time: | 5:15 pm PST |
| Format: | Presentation and Q&A |
The live webcast and replay can be accessed through the “Events” section of Fortrea’s Investor Relations website. Investors interested in one-on-one meetings should contact their banking representatives.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts:
Tracy Krumme (Investors) – 984-385-6707, Tracy.Krumme@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
FAQ
When will Fortrea (FTRE) present at the J.P. Morgan Healthcare Conference?
Who from Fortrea will speak at the J.P. Morgan Healthcare Conference for FTRE?
How can investors watch Fortrea (FTRE) presentation at J.P. Morgan?
Can investors request one-on-one meetings with Fortrea (FTRE) at the conference?
What format will Fortrea's (FTRE) session at J.P. Morgan include?
Where is the J.P. Morgan Annual Healthcare Conference presentation by FTRE taking place?
